Table 3.
Treatment exposure (All Population Propensity Score-Matched)
| Parameter | Abaloparatide N = 11,616 |
Teriparatide N = 11,616 |
|---|---|---|
| Overall treatment duration (days)a | ||
| N | 11,616 | 11,616 |
| Mean (SD) | 301.2 (213.47) | 313.4 (214.95) |
| Median (Interquartile range) | 304 (83, 539) | 331 (84, 546) |
| Overall treatment duration (months)a | ||
| N | 11,616 | 11,616 |
| Mean (SD) | 10.0 (7.12) | 10.4 (7.16) |
| Median (Interquartile range) | 10 (3, 18) | 11 (3, 18) |
| Overall treatment duration, n (%) | ||
| ≤ 1 Month | 2101 (18.1) | 2042 (17.6) |
| > 1 to ≤ 3 Months | 1343 (11.6) | 1173 (10.1) |
| > 3 to ≤ 6 Months | 1187 (10.2) | 1098 (9.5) |
| > 6 to ≤ 9 Months | 885 (7.6) | 922 (7.9) |
| > 9 to ≤ 12 Months | 834 (7.2) | 899 (7.7) |
| > 12 Months | 5266 (45.3) | 5482 (47.2) |
| Cumulative treatment duration (days)c | ||
| N | 11,616 | 11,616 |
| Mean (SD) | 257.8 (192.61) | 269.2 (196.65) |
| Median (Interquartile range) | 224 (60, 450) | 252 (84, 476) |
| Cumulative treatment duration, n (%)c | ||
| ≤ 1 Month | 2110 (18.2) | 2041 (17.6) |
| > 1 to ≤ 3 Months | 1925 (16.6) | 1610 (13.9) |
| > 3 to ≤ 6 Months | 1397 (12.0) | 1371 (11.8) |
| > 6 to ≤ 9 Months | 1095 (9.4) | 1095 (9.4) |
| > 9 to ≤ 12 Months | 1197 (10.3) | 1069 (9.2) |
| > 12 Months | 3892 (33.5) | 4430 (38.1) |
| Consecutive treatment duration, n (%)d | ||
| ≤ 1 Month | 2536 (21.8) | 2533 (21.8) |
| > 1 to ≤ 3 Months | 1646 (14.2) | 1486 (12.8) |
| > 3 to ≤ 6 Months | 1497 (12.9) | 1407 (12.1) |
| > 6 to ≤ 9 Months | 1056 (9.1) | 1037 (8.9) |
| > 9 to ≤ 12 Months | 890 (7.7) | 941 (8.1) |
| > 12 Months | 3991 (34.4) | 4212 (36.3) |
SD, standard deviation
aDuration of exposure (days) = date of last anabolic drug prescription fill plus supply days − index date. Duration of Exposure (months) = duration of exposure (days)/30. The maximum treatment duration is set as 570 days (or 19 months, 18 months plus 30-day follow-up) if a patient was treated longer than 570 days
bAccording to product label, one abaloparatide pen has a 30-day supply; one teriparatide pen has a 28-day supply. Count as 2 pens if day’s supply is between 56 and 60; count as 3 pens if day’s supply is between 84 and 90
cCumulative treatment duration is the sum of all days from index date to the last drug supply date regardless of treatment gap
dConsecutive treatment duration is sum of all days from index date to the last study drug supply without any gap exceeding 60 days